Viatris Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-11-16
- Employees
- 38K
- Market Cap
- $13.9B
- Website
- http://www.viatris.com
Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Viatris Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06471088
- Locations
- 🇰🇷
Viatris, Seoul, Korea, Republic of
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Phase 1
Not yet recruiting
- Conditions
- Bioequivalence Study
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Viatris Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06273254
- Locations
- 🇹ðŸ‡
Medica Innova Co Ltd, Bangkok, Thailand
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Phase 1
Not yet recruiting
- Conditions
- Chronic Heart Failure
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Viatris Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06266988
© Copyright 2025. All Rights Reserved by MedPath